Baricitinib clinical trials

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

This study is looking into whether a medicine called baricitinib can delay Type 1 Diabetes in children and adults who are at a high risk of developing it. It's a key step in preventing the condition.

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

This study is testing a new medicine, baricitinib, for children and teenagers aged 2 to 17 with moderate to severe eczema. Researchers want to see if it's safe and helps improve their skin compared to a dummy pill or usual treatments.

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

This study is looking at a new medicine called baricitinib for children and young people aged 2 to 17 who have a specific eye condition called uveitis. We want to see if it's safe and helps reduce eye inflammation, especially for those who haven't responded well to other treatments.

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

This study investigates if a drug called baricitinib can protect the body's insulin-making cells in children and adults newly diagnosed with type 1 diabetes. It aims to see if preserving these cells helps manage the condition better.

PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial

This study is looking for better ways to treat sepsis in adults. It's testing several existing medicines to see if any work well for different types of sepsis. The main goals are to improve survival and help patients recover without needing machines to support their bodies.

Randomised Evaluation of COVID-19 Therapy

The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

This study looks at a medicine called baricitinib for children aged 1 to 17 with Juvenile Idiopathic Arthritis (JIA). It checks if the medicine is safe and helps treat their JIA. Participants have been in previous baricitinib studies for JIA.

I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis

MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial

I4V-MC-KHAB: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19